Metabolism Des LAM

Acute Myeloid Leukemia Clinical Trial

— LAM-ROS  

Official title:

Rôle Pronostique Des métabolismes du Stress Oxydatif et du Fer Dans Les Leucémies Aiguës Myéloblastiques

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02176109
• Other study ID #: gre-lam-fer
• Secondary ID: Métabolismes des
• Status: Recruiting
• Phase: N/A
• First received: June 24, 2014
• Last updated: June 25, 2014
• Start date: June 2013
• Est. completion date: June 2018

Study information

• Verified date: June 2013
• Source: University Hospital, Grenoble
• Contact: pascal mossuz, phd
• Email: pmossuz[@]chu-grenoble.fr
• Is FDA regulated: No
• Health authority: France: Agence française de sécurité sanitaire des produits de santé
• Study type: Observational

Clinical Trial Summary

In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.

Description:

Primary goal of this study is to Evaluate the characteristics of regulatory networks of iron and redox balance in leukemic cells, to study the correlations between the prognosis of AML patients (in terms of response to induction chemotherapy and survival i) and metabolism of these markers. Secondary ones areto assess the impact of induction therapy on markers of oxidative stress and to correlate biological iron and redox metabolism with the molecular status of patients (eg Flt3/IDH/CEBPA/NPM...).

Eligibility criteria are patients at diagnostic of de novo acute myeloid leukemia (promyelocytic excluded) aged from 18 to 100 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 2018
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

de novo acute myeloid leukemic patient from 18 years to 99 years at diagnosis

Exclusion Criteria:

age under 18 years promelocytic leukemia secondary leukemia

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Diagnosis
• Iron
• Leukemia, Myeloid, Acute
• Oxydative Stress

Locations

Country	Name	City	State
France	University Hospital Grenoble	Grenoble	Isere

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival Event-free survival Response to induction chemotherapy, overalll survival, event-free survival		five years after the inclusion	Yes